Loading…
Loading…
HILLSIDE, NJ / ACCESS Newswire / May 8, 2026 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2026. Revenue for the quarter ended March 31, 2026 was $10.1 million compared to $13.9 million for the quarter ended March 31, 2025, a decrease of $3.8 million or 27.3%.
HILLSIDE, NJ / ACCESS Newswire / February 11, 2026 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2025. Revenue for the quarter ended December 31, 2025 was $11.3 million compared to $12.6 million for the quarter ended December 31, 2024, a decrease of $1.3 million or 10.3%.
LAUPHEIM, Germany and MARTINSRIED, Germany and MUNICH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization (CRDO) and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.
HILLSIDE, NJ / ACCESS Newswire / November 10, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2025. Revenue for the quarters ended September 30, 2025 was $12.7 million compared to $13.6 million for the quarter ended September 30, 2024, a decrease of $0.9 million or approximately 6.6%.
HILLSIDE, NJ / ACCESS Newswire / September 23, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2025. Revenue for the quarter ended June 30, 2025 was $14.2 million compared to $12.7 million for the quarter ended June 30, 2024, an increase of $1.5 million or 11.8%.
HILLSIDE, NJ / ACCESS Newswire / May 14, 2025 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2025. Revenue for the quarter ended March 31, 2025 was $13.9 million compared to $13.1 million for the quarter ended March 31, 2024, an increase of $0.8 million or 6.1%.
HILLSIDE, NJ / ACCESS Newswire / February 13, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2024. Revenue for the quarter ended December 31, 2024 was $12.6 million compared to $11.5 million for the quarter ended December 31, 2023, an increase of $1.1 million or 9.6%.
HILLSIDE, NJ / ACCESSWIRE / November 13, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2024. Revenue for the quarter ended September 30, 2024 was $13.6 million compared to $12.9 million for the quarter ended September 30, 2023, an increase of $0.7 million or approximately 5.4%.